ArticleCNS drugs2019

Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".

Georgios Tsivgoulis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.